[1] Beard JR, Officer A, de Carvalho IA, et al. The world report on ageing and health: a policy framework for healthy ageing. Lancet 2016; 387: 2145−2154. doi: 10.1016/S0140-6736(15)00516-4 [2] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204−1222. doi: 10.1016/S0140-6736(20)30925-9 [3] Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119−177. doi: 10.1093/eurheartj/ehx393 [4] Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289−1367. doi: 10.1093/eurheartj/ehaa575 [5] Gaba P, Gersh BJ, Ali ZA, et al. Complete versus incomplete coronary revascularization: definitions, assessment and outcomes. Nat Rev Cardiol 2021; 18: 155−168. doi: 10.1038/s41569-020-00457-5 [6] Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015; 386: 665−671. doi: 10.1016/S0140-6736(15)60648-1 [7] Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med 2019; 381: 1411−1421. doi: 10.1056/NEJMoa1907775 [8] Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 2015; 65: 963−972. doi: 10.1016/j.jacc.2014.12.038 [9] Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e4−e17. doi: 10.1161/CIRCULATIONAHA.121.058519 [10] Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64: e139−e228. doi: 10.1016/j.jacc.2014.09.017 [11] D’Ascenzo F, Abu-Assi E, Raposeiras-Roubín S, et al. BleeMACS: rationale and design of the study. J Cardiovasc Med (Hagerstown) 2016; 17: 744−749. doi: 10.2459/JCM.0000000000000362 [12] Bainey KR, Engstrøm T, Smits PC, et al. Complete vs culprit-lesion-only revascularization for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. JAMA Cardiol 2020; 5: 881−888. doi: 10.1001/jamacardio.2020.1251 [13] Gershlick AH, Banning AS, Parker E, et al. Long-term follow-up of complete versus lesion-only revascularization in STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 2019; 74: 3083−3094. doi: 10.1016/j.jacc.2019.10.033 [14] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87−165. doi: 10.1093/eurheartj/ehy394 [15] Pavasini R, Biscaglia S, Barbato E, et al. Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2020; 41: 4103−4110. doi: 10.1093/eurheartj/ehz896 [16] Rathod KS, Koganti S, Jain AK, et al. Complete versus culprit-only lesion intervention in patients with acute coronary syndromes. J Am Coll Cardiol 2018; 72: 1989−1999. doi: 10.1016/j.jacc.2018.07.089 [17] Sardella G, Lucisano L, Garbo R, et al. Single-staged compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J Am Coll Cardiol 2016; 67: 264−272. doi: 10.1016/j.jacc.2015.10.082 [18] Andreotti F, Rocca B, Husted S, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015; 36: 3238−3249. doi: 10.1093/eurheartj/ehv304 [19] Madhavan MV, Gersh BJ, Alexander KP, et al. Coronary artery disease in patients ≥ 80 years of age. J Am Coll Cardiol 2018; 71: 2015−2040. doi: 10.1016/j.jacc.2017.12.068 [20] Mehta SR, Bossard M. Acute coronary syndromes and multivessel disease: completing the evidence. JACC Cardiovasc Interv 2020; 13: 1568−1570. doi: 10.1016/j.jcin.2020.05.041 [21] Rittger H, Hochadel M, Behrens S, et al. Age-related differences in diagnosis, treatment and outcome of acute coronary syndromes: results from the German ALKK registry. EuroIntervention 2012; 7: 1197−1205. doi: 10.4244/EIJV7I10A191 [22] Baumann AAW, Tavella R, Air TM, et al. Prevalence and real-world management of NSTEMI with multivessel disease. Cardiovasc Diagn Ther 2022; 12: 1−11. doi: 10.21037/cdt-21-518 [23] Berezhnoi K, Kokov L, Vanyukov A. Effects of complete revascularization on long-term treatment outcomes in patients with multivessel coronary artery disease over 80 years of age admitted for acute coronary syndrome. Cardiovasc Diagn Ther 2019; 9: 301−309. doi: 10.21037/cdt.2018.12.04 [24] Agra-Bermejo R, Cordero A, Veloso PR, et al. Long term prognostic benefit of complete revascularization in elderly presenting with NSTEMI: real world evidence. Rev Cardiovasc Med 2021; 22: 475−482. doi: 10.31083/j.rcm2202054 [25] Harada M, Miura T, Kobayashi T, et al. Clinical impact of complete revascularization in elderly patients with multi-vessel coronary artery disease undergoing percutaneous coronary intervention: a sub-analysis of the SHINANO registry. Int J Cardiol 2017; 230: 413−419. doi: 10.1016/j.ijcard.2016.12.093 [26] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: e574−e651. doi: 10.1161/CIR.0b013e31823ba622 [27] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541−2619. doi: 10.1093/eurheartj/ehu278 [28] Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: 156−175. doi: 10.1161/CIRCULATIONAHA.105.170815 [29] Biscaglia S, Guiducci V, Santarelli A, et al. Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: rationale and design of the FIRE trial. Am Heart J 2020; 229: 100−109. doi: 10.1016/j.ahj.2020.08.007 [30] Alegre O, Formiga F, López-Palop R, et al. An easy assessment of frailty at baseline independently predicts prognosis in very elderly patients with acute coronary syndromes. J Am Med Dir Assoc 2018; 19: 296−303. doi: 10.1016/j.jamda.2017.10.007